Tong Cheng

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Rutgers, The State University of New Jersey. Active years: 2015-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tong Cheng. Retrieved from https://idiyas.com/inventor/tong-cheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.7

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Fujian Province, CN (2018 - 2022)
Xiamen, CN (2015 - 2023)

Company Filing History:

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

patents

3 out of 1,498

Rutgers, The State University of New Jersey

patents

4. 3 out of 13

Yang Sheng Tang Company Limited

patents

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11793844 - Virus for treatment of tumor (2023-10-24),

2. 11707496 - Echovirus for treatment of tumors (2023-07-25),

3. 11220673 - ORF7 deficient varicella virus, vaccine comprising the virus and use thereof (2022-01-11),

4. 10752885 - ORF7 deficient varicella virus, vaccine comprising the virus and use thereof (2020-08-25),

5. 9885020 - ORF7 deficient varicella virus, vaccine comprising the virus and use thereof (2018-02-06),

6. 9222090 - RNA interference target for treating AIDS (2015-12-29),

Title: Innovations of Inventor Tong Cheng

Introduction

Tong Cheng is a notable inventor based in Province, China, recognized for his significant contributions to the field of medical research. He holds a total of six patents, showcasing his innovative approach to treating tumors through viral therapies. His work has the potential to impact cancer treatment significantly.

Latest Patents

Among his latest patents, Cheng has developed a virus for the treatment of tumors, specifically utilizing enterovirus D68 (EV-D68) or its modified forms. This patent includes a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68, which can be used in pharmaceutical compositions aimed at treating tumors. Another significant patent involves the use of Echovirus 25 (ECHO25) or its modified forms, which also focuses on the treatment of tumors in subjects. These innovations highlight Cheng's commitment to advancing therapeutic options for cancer patients.

Career Highlights

Cheng has had a distinguished career, working at prominent institutions such as Xiamen University and Rutgers, the State University of New Jersey. His research has been pivotal in exploring the therapeutic applications of viruses in oncology, contributing to the understanding of how these agents can be harnessed for medical benefits.

Collaborations

Cheng has collaborated with esteemed colleagues, including Ningshao Xia and Xiangzhong Ye. These partnerships have fostered a collaborative environment that enhances the research and development of innovative treatments.

Conclusion

Tong Cheng's work exemplifies the intersection of innovation and medical research, particularly in the field of cancer treatment. His patents reflect a forward-thinking approach that could lead to groundbreaking advancements in oncology.

Profile summary based on public USPTO records.